← Leaderboards
Timothy J Yeatman
University Of South Florida
$17,520,103
Attributed
$18,443,476
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $977.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,443,476 · 12
By mechanism
U01$9,492,467 · 3
R01$5,110,581 · 2
R21$1,502,578 · 3
UH3$916,946 · 1
K24$581,209 · 1
S10$500,000 · 1
Top collaborators
- Ganesh V Halade2 shared
- Deepak K Agrawal1 shared
Most similar at University Of South Florida
Same institution · by research overlap
- Jerri Edwards$44,150,574
- Stephen Edward Saddow$301,384
- Jennifer Lee O'Brien$15,110,862
- Brent John Small$1,954,364
- Cecile A Lengacher$5,858,173
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorGenesMolecularGene MutationSamplingEnsureBaseValidationCell LineClinical TrialsNeoplasm /Cancer GeneticsColorectal CancerCancer TherapyPharmaceutical PreparationsGene Expression ProfileMutationResponseSpecimenClinical ResearchMutateBraf GeneEpidermal Growth Factor ReceptorFutureMutant
Grant awards (44)
Interrogating the role of arachidonic acid metabolism in modulating the tumor immune microenvironment as a novel path to therapeutic intervention$622,227
U01 · FY2025 · CA · contact PI
Interrogating the role of arachidonic acid metabolism in modulating the tumor immune microenvironment as a novel path to therapeutic intervention$624,518
U01 · FY2024 · CA · contact PI
CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE$309,375
UH3 · FY2023 · CA · contact PI
CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE$298,758
UH3 · FY2022 · CA · contact PI
APC + TP53 Combinatorial Mutations Emerging as Biomarkers to Predict EGFRI Sensitivity$171,233
R21 · FY2022 · CA · contact PI
Detection of Colorectal Cancer Adaptive Mutability May Justify Combination of Targeted- and Immune-Therapies$323,344
R21 · FY2021 · CA · contact PI
CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE$308,813
UH3 · FY2021 · CA · contact PI
APC + TP53 Combinatorial Mutations Emerging as Biomarkers to Predict EGFRI Sensitivity$213,881
R21 · FY2021 · CA · contact PI
Detection of Colorectal Cancer Adaptive Mutability May Justify Combination of Targeted- and Immune-Therapies$68,770
R21 · FY2021 · CA · contact PI
CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE$339,695
UH2 · FY2019 · CA · contact PI
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE$495,417
U01 · FY2016 · CA · contact PI
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE$500,421
U01 · FY2015 · CA · contact PI
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE$134,668
U01 · FY2015 · CA · contact PI
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE$481,480
U01 · FY2014 · CA · contact PI
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE$134,668
U01 · FY2014 · CA · contact PI
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE$468,328
U01 · FY2013 · CA · contact PI
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE$600,002
U01 · FY2012 · CA · contact PI
Illumina iScan system with processing equipment for the Infinium and GoldenGate B$500,000
S10 · FY2010 · RR · contact PI
Chip-Based Diagnosis of Problematic Liver Tumors$436,661
R01 · FY2010 · CA · contact PI
Chip-Based Diagnosis of Problematic Liver Tumors$429,158
R01 · FY2009 · CA · contact PI
Chip-Based Diagnosis of Problematic Liver Tumors$93,520
R01 · FY2009 · CA · contact PI
Chip Based Diagnosis of Problematic Liver Tumors$417,714
R01 · FY2008 · CA · contact PI
Chip-Based Diagnosis of Problematic Liver Tumors$93,007
R01 · FY2008 · CA · contact PI
Screening for Breast Cancer Using Molecular Signatures$569,440
R01 · FY2007 · CA · contact PI
Chip Based Diagnosis of Problematic Liver Tumors$407,162
R01 · FY2007 · CA · contact PI
Screening for Breast Cancer Using Molecular Signatures$569,770
R01 · FY2006 · CA · contact PI
Chip-Based Diagnosis of Problematic Liver Tumors$407,505
R01 · FY2006 · CA · contact PI
Screening for Breast Cancer Using Molecular Signatures$566,092
R01 · FY2005 · CA
DECODING FINGERPRINTS PORTENDING COLON CANCER METASTASIS$1,240,483
U01 · FY2004 · CA
Screening for Breast Cancer Using Molecular Signatures$549,601
R01 · FY2004 · CA
Molecular Profiling to Predict Response to Chemotherapy$362,675
R21 · FY2004 · CA
SRC AS A NOVEL TARGET FOR HUMAN COLON CANCER THERAPY$116,317
K24 · FY2004 · CA
DECODING FINGERPRINTS PORTENDING COLON CANCER METASTASIS$21,807
U01 · FY2004 · CA
DECODING FINGERPRINTS PORTENDING COLON CANCER METASTASIS$1,228,199
U01 · FY2003 · CA
Screening for Breast Cancer Using Molecular Signatures$570,951
R01 · FY2003 · CA
Molecular Profiling to Predict Response to Chemotherapy$362,675
R21 · FY2003 · CA
SRC AS A NOVEL TARGET FOR HUMAN COLON CANCER THERAPY$116,317
K24 · FY2003 · CA
DECODING FINGERPRINTS PORTENDING COLON CANCER METASTASIS$18,174
U01 · FY2003 · CA
DECODING FINGERPRINTS PORTENDING COLON CANCER METASTASIS$1,182,296
U01 · FY2002 · CA
SRC AS A NOVEL TARGET FOR HUMAN COLON CANCER THERAPY$116,317
K24 · FY2002 · CA
DECODING FINGERPRINTS PORTENDING COLON CANCER METASTASIS$1,112,110
U01 · FY2001 · CA
SRC AS A NOVEL TARGET FOR HUMAN COLON CANCER THERAPY$116,317
K24 · FY2001 · CA
DECODING FINGERPRINTS PORTENDING COLON CANCER METASTASIS$627,669
U01 · FY2000 · CA
SRC AS A NOVEL TARGET FOR HUMAN COLON CANCER THERAPY$115,941
K24 · FY2000 · CA